CYP19A1 and breast carcinoma: It has been observed that co-administration of aromatase inhibitor and microtubule-modulating drugs can improve clinical effectiveness in breast cancer patients.11,12 Despite of these positive outcomes, such combinations can increase the risk of adverse effects, drug interactions, and detrimental physiological change.